Organization | Universidad Europea de Madrid

Universidad Europea de Madrid Report issue

Academic/Hospital Phase 4

Founded: Madrid Spain (1995)

Organization Overview

First Clinical Trial

2015

NCT02593721

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Confederación Gallega de Discapacidad | Francisco Unda Solano | Universidad Europea de Madrid | Universidad Europea de Madrid (Madrid) | Vanesa Abuín

Active Ingredients

Drugs in Phase 4 Trials (2)

gabapentin (neurontin) (2 trials)

ibuprofen (motrin) (4 trials)

Drugs in Other Trials (11)

bifidobacterium bifidum (1 trial)

cocoa bean (1 trial)

cocoa extract (1 trial)

cocoa flavanols (2 trials)

ivacaftor (Kalydeco) (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus casei (1 trial)

lactobacillus rhamnosus (1 trial)

lumacaftor (Orkambi) (1 trial)

vitamin c (2 trials)

vitamin e (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Brachial Plexus Neuritis (Phase 3)

Carpal Tunnel Syndrome (Phase 4)

Chronic Pain (Phase 4)

Neuralgia (Phase 3)

Syndrome (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 13
# of Trial APIs: 13